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ABSTRACT 
Schizophrenia is one of the most debilitating neuropsychiatric disorders, with a 
prevalence of approximately 1% worldwide.  Symptoms include impairing deficits in 
cognitive processes (e.g., working memory, attention, and cognitive flexibility) which are 
currently elusive to treatment.  Alpha-7 nicotinic acetylcholine receptors (α7 nAChRs) 
may be a critical link between the dysregulated cortical glutamatergic transmission and 
cognitive deficits in schizophrenia.  Elevated levels of the endogenous, astrocyte-derived 
neuromodulator kynurenic acid (KYNA), a potent, non-competitive α7 nAChR antagonist, 
in the brains and cerebrospinal fluid (CSF) of schizophrenic patients suggests that KYNA 
binding may cause or exacerbate cortical dysregulation in schizophrenia.  Thus, we used 
a state-of-the-art microelectrode array (MEA) to amperometrically examine the 
regulation of glutamate release by KYNA in the prefrontal cortex (PFC) of intact, freely 
moving rats.  The MEA allows for the selective quantification of glutamate levels with 
second-by-second resolution (500-800 ms), a limit of detection of ≤0.5 µM, and 
outstanding spatial resolution (<100 µm).  Intraperitoneal (i.p.) injections of L-kynurenine 
(25 and 50 mg/kg), KYNA’s bioprecursor, dose-dependently decreased basal glutamate 
levels in PFC (nadir after 50 mg/kg kynurenine: 31% decrease from baseline values).  
However, co-administration of galantamine (3 mg/kg), a drug that competes with KYNA 
at an allosteric potentiating site of the α7 nAChR, attenuated kynurenine-mediated 
reductions in cortical glutamate.  These data in intact animals demonstrate KYNA’s α7 
nAChR-mediated regulation of glutamate release in the PFC.  Drugs that normalize 
cortical glutamatergic function by attenuating KYNA production or by countering its 
effects on α7 nAChRs may be effective cognition-enhancing therapeutics in 
schizophrenic patients. 
Note: The experiments presented in this thesis also appear in a manuscript 
(Konradsson-Geuken et al., 2010), which is in revisions for the journal Neuroscience. 
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INTRODUCTION 
Schizophrenia is one of the most severe and debilitating neuropsychiatric 
disorders, with a prevalence of approximately 1% worldwide (Perala et al., 2007).  The 
disease results from the interaction of multiple genetic and environmental factors, 
independent of geographic, cultural, or socio-economic variables (Harrison & 
Weinberger, 2005).   The characteristic symptoms of schizophrenia fall into three 
categories: positive, negative, and cognitive symptoms (Andreasen, 1995).  Positive 
symptoms reflect the distortion of normal thoughts in both form and content, and include 
hallucinations and delusions.  Negative symptoms involve the decline or loss of normal 
behavior, and include affective flattening and social withdrawal.  Cognitive symptoms 
result from impairments in executive function, and include deficits in working memory, 
attention, and cognitive flexibility.   
While positive symptoms in most patients are reduced with first generation 
antipsychotic drugs (FGAs), these treatments have minimal effect ameliorating negative 
and cognitive symptoms, and may even exacerbate them (King, 1998).  Treatment with 
FGAs is associated with a high incidence of extrapyramidal side-effects (EPS), such as 
acute dystonia and parkinsonism (Hansen et al., 1997). Treatment with second 
generation antipsychotic drugs (SGAs; e.g., clozapine) reduces positive symptoms, 
results in a lower incidence of EPS, and also has some effect reducing negative 
symptoms (Dayalu & Chou, 2008).  However, SGAs may cause severe side effects 
which can lead to diabetes or cardiovascular disease (Kane et al., 1988).  Despite 
significant advances in pharmacological treatment, nevertheless, schizophrenia remains 
prevalent and debilitating, largely due to the absence of treatments that address the 
disruptions in executive function.  These impairments are integral because they 
accompany (Saykin et al., 1994) and may even predate the first psychotic episode 
(Jones et al., 1994).  Additionally, there is a positive correlation between the severity of 
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cognitive dysfunction and the declining quality of life of schizophrenic patients (Green et 
al., 1996).  The cognitive class of symptoms in schizophrenia is also the most predictive 
of social disintegration.  Thus, the cognitive deficits of schizophrenia are the most 
devastating symptoms, but are also currently the most elusive in treatment (Keefe, 
2007).   
Recent clinical findings support the theory that dysregulated cortical 
glutamatergic transmission contributes to the pathophysiology of schizophrenia (Lewis & 
Moghaddam, 2006; Patil et al., 2007).  The ability of phencyclidine, a glutamate N-
methyl-D-aspartic acid receptor (NMDA-R) antagonist, to induce schizophrenia-like 
symptoms in healthy volunteers (Luby et. al, 1962) and to exacerbate the psychotic 
symptoms and cognitive deficits in schizophrenic patients (Javitt & Zukin, 1991) is the 
strongest evidence linking glutamatergic dysfunction to the pathophysiology of 
schizophrenia. 
There is also evidence that altered cortical cholinergic function is a contributing 
factor in schizophrenia (Hyde and Crook, 2001; Sarter et al., 2005).  Post-mortem 
studies have reported a decrease in muscarinic (Crook et al., 2001) and nicotinic 
(Breese et al., 2000) ACh receptor binding in the prefrontal cortex of schizophrenic 
patients.  The focus on the alpha7 nicotinic ACh receptor (α7 nAChR) is based upon 
demonstrations of a) impaired nicotinic ACh transmission in schizophrenia (Leonard & 
Freedman, 2006), b) reduced expression of the α7 nAChR protein in the prefrontal 
cortex (PFC) of schizophrenic patients (Guan et al., 1999), c) an association between 
the α7 nAChR gene and disease transmission (Martin et al., 2007), and d) cognition-
enhancing effects of nAChR agonists in schizophrenic patients (Olincy et al., 2006).  In 
fact, there is a growing literature in animals (Levin & Rezvani, 2007) and humans (Harris 
et al., 2004) that stimulation of nAChRs (particularly the α7 subtype) is associated with 
the facilitation of several cognitive behaviors including working memory and attention.  
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Due to the localization of release-promoting α7 nAChR on cortical glutamatergic and 
cholinergic nerve terminals (Gotti et al., 2006; Lambe et al., 2003; Dickinson et al., 2008; 
Duffy et al., 2009) as well as the proximity of cholinergic and glutamatergic terminals in 
the PFC (Marchi et al., 2002; Rousseau et al., 2005; Wang et al., 2006; Konradsson-
Geuken et al., 2009), it is likely that α7 nAChRs also mediate cortical glutamate release.  
Thus, impairments in cholinergic and glutamatergic functioning may be critical links 
between the dysregulated prefrontal circuitry underlying the cognitive deficits in 
individuals with schizophrenia (Sarter et al., 2005). 
The relevance of glutamate and acetylcholine (ACh) hypofunction is also 
supported by elevated levels of kynurenic acid (KYNA), a potent non-competitive α7 
nAChR antagonist (Hilmas et al., 2001) in the brain (Schwarcz et al., 2001) and 
cerebrospinal fluid (CSF; Erhardt et al., 2001) of post-mortem schizophrenic patients.  
KYNA is a metabolite of the kynurenine pathway of tryptophan degradation (Kiss et al., 
2003; see Figure 1), and is formed by the transamination of L-kynurenine (kynurenine) 
catalyzed by several kynurenine aminotransferases (KAT; Turski et al., 1989), especially 
KAT II.  A major locus of the enzyme KAT II is astrocytes (Guidetti et al., 2007), which 
subsequently release KYNA into the extracellular milieu (Turski et al., 1989; see Figure 
2).  At nanomolar concentrations, KYNA negatively modulates α7 nAChRs by binding to 
an allosteric site (Lopes et al., 2007).  Recent studies investigating the bi-directional 
effects of fluctuating KYNA concentrations on dopamine, ACh, and glutamate in the PFC 
(Wu et al., 2006; Zmarowski et al., 2009; Wu et al., 2010) suggest that KYNA binding 
may cause or exacerbate dysregulation of the PFC in schizophrenia. 
These experiments were designed to examine further the relationship between 
KYNA and glutamate in the PFC.  First, we observed the effects of systemic 
administration of kynurenine, which elevates KYNA levels throughout the brain 
(Rassoulpour et al., 2006), on cortical glutamate levels in the PFC.  As KYNA negatively 
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modulates the α7 nAChR by binding to its allosteric potentiating site (Lopes et al., 2007), 
we previously demonstrated that local infusion of KYNA tends to reduce cortical 
acetylcholine release (Zmarowski et al., 2009).  Furthermore, due to the localization of 
release-promoting nAChRs on cortical glutamate terminals (Gotti et al., 2006), α7 
nAChR ligands will also likely affect cortical glutamate release (Konradsson et al., 2009).  
If basal glutamate release is mediated by the α7 nAChR, it is hypothesized that 
systemic administration of kynurenine (25 mg/kg or 50 mg/kg), a bio-precursor to KYNA 
(see Figures 1 and 2), will dose-dependently decrease basal glutamate levels in PFC. 
Next, additional animals were co-administered galantamine with kynurenine to 
test whether the effects of KYNA on glutamate levels were in fact mediated by α7 
nAChRs.  Galantamine, an allosteric potentiating ligand (APL) of the α7 nAChR, binds to 
a site similar to that bound by the negative modulator KYNA, but with opposite effects 
(Lopes et al., 2007).  Pre-clinical studies indicate that, in low (micromolar) doses, 
galantamine acts as a potent positive allosteric modulator of the α7 nAChR (Samochocki 
et al., 2003), and enhances the antipsychotic effects of the typical antipsychotic 
raclopride (Wiker et al., 2008).  The effect of galantamine on cognitive performance 
suggests the prospective benefit of allosteric potentiating ligands of α7 nAChR as 
adjunctive treatments for schizophrenia if administered at effective doses (Buchanan et 
al., 2008).  Thus, if the reductions in cortical glutamate observed in Experiment 1 are in 
fact mediated by α7 nAChR, it is hypothesized that systemic administration of 
galantamine (3 mg/kg; 5 min pre- and 3 hr post-kynurenine injection) will consistently 
attenuate reductions in basal glutamate levels in PFC.   
Extracellular glutamate levels were recorded in freely-moving animals with a 
glutamate-sensitive, amperometric microelectrode array (MEA) which wields unmatched 
temporal and spatial resolution. 
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METHODS 
Animals 
Male Wistar rats weighing 250–450 g were used as subjects in these experiments. 
Animals were maintained in a temperature- and humidity-controlled room on a 12:12-
hour light:dark cycle (lights on at 06:00 a.m.) and individually housed in plastic cages 
lined with corn-cob bedding. Animals had access to food and water ad libitum. All 
procedures involving animals were approved by The Ohio State University Institutional 
Animal Care and Use Committee in accordance with the NIH Guide for the Care and 
Use of Laboratory Animals.  As such, all efforts were made to minimize animal suffering 
and to reduce the number of animals used. 
 
Materials    
L-Kynurenine (sulfate form; ‘kynurenine’), L-ascorbic acid (AA), dopamine (DA), L-
glutamate (monosodium salt), glutaraldehyde [25% (w/v) in water], bovine serum 
albumin (BSA), and H2O2 were obtained from Sigma Aldrich Corp. (St. Louis, MO, USA).  
Galantamine was a research gift from Janssen Pharmaceutica (Beerse, Belgium).  L-
Glutamate oxidase (GluOx; EC 1.4.3.11) was purchased from Seikaghaku America, Inc. 
(East Falmouth, MA, USA).  Meta-phenylenediamine (m-PD) was purchased from Acros 
Organics (Fairlawn, NJ, USA).  All solutions were prepared using distilled, deionized 
water.   
 
Coating of glutamate-sensitive microelectode array 
The MEA used for these freely-moving experiments (Figure 3A) consists of a ceramic 
paddle containing, at its tip, four platinum (Pt) recording sites.  The paddle of the MEA 
interfaces with a pre-amplifier headstage (see Rutherford et al., 2007 for more details on 
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this assemblage).  Figure 3B is a magnified view of the tip of the MEA, revealing the four 
15 x 333 µm Pt recording sites arranged in pairs beginning approximately 100 µm from 
the electrode tip.  One pair of recording sites was designated to be sensitive to 
glutamate plus other endogenous electroactive species and was coated with glutamate 
GluOx (2%, 1 unit/1 µL, 100 nL), bovine serum albumin (BSA, 1%), and glutaraldehyde 
(0.125%).  The remaining pair served as a sentinel site, sensitive to the oxidation of the 
same molecules except for glutamate.  This coating arrangement and the design of the 
MEA allows for a self-referencing procedure (see below) in which the current derived 
exclusively from the oxidation of glutamate can be isolated (Day et al., 2006; Rutherford 
et al., 2007; Konradsson-Geuken et al., 2009).  To control for the micro-environments 
into which a particular pair of sites could be implanted, the positioning of the glutamate-
sensitive versus sentinel sites, relative to the tip of the MEA (i.e., more ventral vs. more 
dorsal pair) was counterbalanced within a treatment condition.  Coated MEAs were 
allowed to dry for ≥ 2 days at room temperature (25°C) and low humidity prior to in vitro 
calibration (see below).  m-PD (5.0 mM) was then electropolymerized onto all sites in 
order to reduce access of potential electroactive interferents, including AA and 
catecholamines, to the Pt recording sites (Mitchell, 2004).  Electroplating was conducted 
in bubbled nitrogen using cyclic voltammetry (peak-to-peak amplitude of 0.25 V every 
0.05 sec for 25 min).   
 
Detection of glutamate-generated signals  
The enzyme detection scheme for generating the current derived by the selective 
oxidation of glutamate is more fully elaborated elsewhere (Day et al., 2006; Rutherford et 
al., 2007; Konradsson-Geuken et al., 2009), but is described briefly in Figure 4 below.   
The various coatings of the Pt electrode surface for the two glutamate sensitive channels 
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are indicated by the shaded columns on the left and a schematic illustrating the two pairs 
of MEA recording sites appears in the middle.  The shaded columns on the far right 
depict the events occurring at the electrode surface of the sentinel channels. In all 
channels, access to the Pt surface by DA is essentially blocked by m-PD.  On the 
glutamate-sensitive channels (Figure 4, left), glutamate is oxidized by GluOx, generating 
α-ketoglutarate and H2O2.  Because the MEA is maintained at a constant potential of 
+0.7 V, the H2O2 reporting molecule is oxidized, yielding two electrons.  The resulting 
current is then amplified and recorded by a FAST-16 mkI recording system (Quanteon, 
LLC, Nicholasville, KY).  On the sentinel channels, extracellular glutamate reaches the 
Pt surface but in the absence of GluOx no oxidation current is generated.  Any current 
detected is due to endogenous electroactive molecules other than glutamate. 
  
In vitro calibration of microelectrodes 
MEAs were calibrated prior to implantation using the FAST-16 mkI electrochemical 
recording system.  Constant potential amperometry was conducted using an applied 
potential of +0.7 V versus a Ag/AgCl reference electrode.  Calibrations were performed 
in a stirred solution of phosphate-buffered saline (PBS; 0.05 M, 40 mL, pH 7.4, 37°C).  
After stabilization, AA (250 µM), glutamate (3 x 20 µM), DA (2 µM), and H2O2 (8.8 µM) 
were sequentially added to the calibration beaker (see Figure 5).  Amperometric signals 
were acquired at a rate of 2.0 Hz. The slope (sensitivity, nA/µM glutamate), limit of 
detection (L.O.D., µM glutamate), selectivity (ratio of glutamate over AA), and linearity 
(R2) were calculated.  In order to be used for subsequent in vivo recordings, the MEAs 
had to conform to the following calibration criteria (single electrode mode): a) similar 
background current (i.e., no greater than a 20 pA difference between the glutamate-
sensitive and sentinel channels), b) linear response to increasing concentrations of 
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glutamate (R2 > 0.998), c) a minimum slope of -3.0 pA/µM glutamate, d) an L.O.D. of 
≤0.5 µM, and e) a high selectivity for glutamate over either AA or DA (i.e., >50:1). 
  
Implantation of microelectrodes 
Animals were anesthetized using isofluorane (2%, 0.6 L/min) and implanted with the 
microelectrode pedestal that contained the MEA and was connected to the miniaturized 
Rat Hat amplifier (Rutherford et al., 2007).  MEAs were implanted unilaterally in the PFC, 
with coordinates determined from the atlas of Paxinos and Watson (1985) (AP: 2.7 mm 
anterior to bregma, ML: ±0.6 mm from midline, DV: 3.9 mm below dura; hemispheres 
counterbalanced within a treatment condition).  The Ag/AgCl reference electrode was 
implanted in a contralateral site distant from the recording area. 
 
In vivo recordings of systemic injections 
All electrochemical recordings in both Experiments 1 and 2 were conducted in freely 
moving rats in a large wooden box (57.2 cm H x 41.9 cm W x 17.0 cm L) 2-6 days after 
implantation of the MEA.  Animals were placed in the recording box and connected to 
the head stage (see Figure 3C).  Stable baseline signals were recorded following a 3-4 
hr habituation period.  In both experiments, the effects of systemic administration of test 
compounds on cortical glutamate were determined.  In the first experiment, rats were 
treated with kynurenine (25 or 50 mg/kg, i.p.; n = 5/dose).  At these doses, KYNA acts as 
a preferential α7 nAChR antagonist (Hilmas et al., 2001).  While KYNA also blocks the 
glycineB site of the NMDA receptor (NMDA-R) with high potency in the absence glycine 
(see Figure 2), under physiological conditions KYNA is unlikely to inhibit NMDA-R 
(Hilmas et al., 2001).  In the second experiment, the hypothesis that the effect of 
kynurenine was mediated by the antagonism of α7 nAChRs was tested.  Thus, we 
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injected galantamine (3.0 mg/kg, i.p.), a positive allosteric modulator at low doses, that 
binds at a site of the α7 nAChR that is very similar to that targeted by KYNA (Lopes et 
al., 2007), 5 min prior to kynurenine (50 mg/kg, n = 5).  Recordings continued for 6 hrs 
post-injection.  Another group of rats (n = 5) was injected with both kynurenine and 
galantamine except that, in this case, the administration of galantamine was delayed 
until 3 hrs post-kynurenine. 
 
Histology 
At the conclusion of each experiment, animals were anesthetized with isoflourane and 
then given an overdose of pentobarbital.  Brains were removed and stored in formalin 
(10%) for at least 24 hours, and then transferred to a sucrose solution (30%) for at 
least 3 days.  Brains were sectioned using a cryostat; coronal (see Figure 6) and sagittal 
sections (50 µm) were mounted on gelatin-coated slides, stained using cresyl violet, and 
examined under a light microscope for verification of MEA placement in the PFC. 
  
Data analyses 
For the microelectrode experiments, group comparisons of absolute glutamate levels or 
various temporal dimensions of the glutamate signal were analyzed using one- and two-
way analysis of variance.  In some instances, when only percentage data were being 
compared, t-tests between independent means were utilized.  Significance was defined 
as P < 0.05.  All statistical tests were performed using SPSS for Windows (Version 17.0; 
Chicago, IL). 
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RESULTS 
The following experiments utilized the glutamate-sensitive MEA to examine the 
effects of fluctuating KYNA levels on basal glutamate levels in the prefrontal cortex.  
Prior to implantation, MEAs were calibrated in a beaker with known concentrations of 
potential analytes.  Figure 5 illustrates the results of a representative in vitro calibration.  
Current tracings following the administration of AA, glutamate, DA, and H2O2 (indicated 
by arrows) are shown from each of the 4 channels.  The top two tracings (GluOx) depict 
current at the glutamate-sensitive channels, whereas the bottom two tracings (sentinel) 
illustrate current from the sentinel or background channels.  The addition of AA to the 
beaker produced only minor increases in oxidation current, which were, importantly, 
comparable on all 4 channels.  Serial additions of glutamate (20 µM aliquots) produced 
large, reproducible, and linear increases in current at the GluOx sites as the 
concentration of glutamate in the beaker was progressively elevated.  In contrast, the 
signal on the sentinel channels did not change as a result of the addition of glutamate.  
Addition of DA produced only a slight change in current, indicating the effectiveness of 
the exclusion barrier m-PD, and this modest increase was comparable across the 4 
channels.  Finally, all 4 recording sites exhibited similar sensitivity to the reporter 
molecule, H2O2, which is a necessary condition for the self-referencing procedure used 
to isolate the current change caused by the oxidation of glutamate (Burmeister and 
Gerhardt, 2001). 
 
Experiment 1a:  Effects of systemic kynurenine on cortical glutamate levels  
  Figure 7 shows a representative MEA tracing following the systemic 
administration of kynurenine (50 mg/kg, i.p.).  After the establishment of a stable 
baseline, kynurenine produced a gradual and protracted reduction in signal at the 
glutamate-sensitive site (top tracing, “GluOx”).  There was only a minor negative drift in 
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the current output at the background sentinel site (second tracing, “Sentinel”).  Self-
referencing the sentinel from the GluOx sites yielded a signal that isolated current 
changes due only to the oxidation of glutamate (third tracing, “KYN self-ref”).  The 
kynurenine-induced decrease in extracellular glutamate reached a maximum of -2.1 µM 
(-23%) from baseline by the end of the 6 hr recording session.  Importantly, a control 
procedure conducted at the end of each session verified that the MEA had maintained 
its ability to record changes in extracellular glutamate levels.  Thus, a local infusion of 
exogenous glutamate (0.25 mM) into the PFC at the nadir of the current output elicited a 
rapid and pronounced increase in signal.  As prior studies reported that H2O2 is oxidized 
primarily at +0.7 V at the Pt recording sites versus Ag/AgCl, control recordings 
conducted at +0.25 V eliminated any differences between the GluOx and sentinel sites, 
verifying the glutamate signals in vivo (Pomerleau et al., 2003; data not shown).  These 
observations were consistent with the interpretation that the self-referenced signal is 
generated by the oxidation of glutamate-derived H2O2 (Rutherford et al., 2007).  The 
bottom tracing in Figure 7 (“Saline Self Ref”) illustrates a representative self-referenced 
record from an animal receiving a control injection of saline (0.9%, i.p.).  This provides 
evidence that the injection per se did not lead to significant changes in current and that 
the signal was relatively stable over the entire recording session. 
Table 1 summarizes group data on the magnitude and timing of the changes in 
the glutamate signal.  Overall, kynurenine (50 mg/kg, n = 5) caused a significant 
decrease (-31%) compared to basal glutamate levels (t4 = 4.67, P = 0.009).  This 
reduction was evident within 6 min of the injection and reached a maximum 5 hrs later.  
This effect of kynurenine persisted throughout the 6 hr recording session. 
 
Experiment 1b:  Dose-dependency of kynurenine-mediated reductions in cortical 
glutamate levels 
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The ability of systemic kynurenine to decrease prefrontal glutamate levels was 
dose-dependent.  Figure 8 illustrates the tracings from a representative animal treated 
with 25 mg/kg kynurenine (i.p.) (n = 5).  While the baseline glutamate signal was similar 
to that seen when studying the effects of the higher dose, administration of the lower 
dose produced an effect that was smaller in magnitude (-1.3 µM, -12% from baseline) 
and of shorter duration (return to baseline within 4 hrs) than the reduction caused by the 
higher dose (cf. Figure 7).  As summarized in the group data (Table 1), 25 mg/kg 
kynurenine caused a significant decrease (-11%) from basal glutamate levels (t4 = 3.83, 
P = 0.019).  Glutamate levels were reduced within 16 min after kynurenine and returned 
to basal values within 3 ½ hrs of the injection.  50 mg/kg kynurenine produced greater 
reductions in glutamate levels than 25 mg/kg (F1,8 = 7.71, P = 0.02).  While there was no 
significant dose-dependent difference in the onset of the effect, the time to reach 
maximal effect (F1,9 = 44.70, P < 0.001) and effect duration (F1,9 = 47.99, P < 0.001) 
were significantly longer for the higher dose than for the smaller dose.  The dose- and 
time-dependent effects of systemically administered kynurenine on extracellular levels of 
KYNA and glutamate in the PFC are illustrated in Table 1.                     
 
Experiment 2: Tonic effects of co-administration of systemic galantamine and 
kynurenine on basal cortical glutamate levels 
The kynurenine-induced reduction of prefrontal glutamate levels reflected the 
ability of increased KYNA levels to antagonize the α7 nAChR.  Thus, pre-treatment with 
the positive α7 nAChR-modulator galantamine (3.0 mg/kg, i.p.) markedly attenuated the 
effects of 50 mg/kg kynurenine.  Figure 9 illustrates a representative current tracing from 
the galantamine/kynurenine combination.  The third trace from the top (“Gal/Kyn Self 
Ref”) depicts the self-referenced glutamate signal following the combined treatment.  
Compared to the profile seen following 50 mg/kg kynurenine alone (Figure 7), the 
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combination of the two compounds produced a smaller maximal effect on glutamate (-
1.3 µM), which reverted more quickly to basal levels (2 ½ hrs).  The group data listed in 
Table 1 show that the combination of galantamine and kynurenine (n = 5) led to smaller 
decreases in glutamate (F1,9 = 13.34, P = 0.006) and also shorter durations of the 
inhibition (F1,9 = 255.36,  P < 0.001) relative to kynurenine alone.  In fact, pre-treatment 
with galantamine rendered the effects of 50 mg/kg kynurenine similar to the profile seen 
following the application of 25 mg/kg kynurenine alone.  Treatment with galantamine, 
however, reduced the time to maximum effect relative to either dose of kynurenine (F1,9 
= 6.28, P = 0.04).  
The bottom trace in Figure 9 (“Kyn-Gal Self Ref”) illustrates a similar experiment, 
but the administration of galantamine was delayed until 3 hrs after the injection of 
kynurenine (50 mg/kg), when the inhibitory effect of kynurenine on glutamate was 
pronounced.  Galantamine caused a clear reversal of the glutamate signal, which 
returned to baseline values within 90 min. These results demonstrated that the 
kynurenine-induced decrease in glutamate is consistently mediated by the α7 nAChR. 
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DISCUSSION 
Previous studies suggest that the astrocyte-derived α7 nAChR antagonist KYNA, 
in endogenous (nanomolar) concentrations, indirectly modulates extracellular glutamate 
levels (Konradsson et al., 2009; Wu et al., 2010).  The experiments in this thesis further 
investigated the interaction between KYNA and prefrontal glutamate release, revealing 
that systemic administration of KYNA’s bioprecursor kynurenine results in dose-
dependent reductions in cortical glutamate levels in the PFC.  Furthermore, systemic co-
administration of the positive α7 nAChR modulator galantamine either prevented or 
attenuated this reduction of extracellular glutamate release.  These data, as recorded by 
the MEA, yielded results that were qualitatively and quantitatively similar to those 
produced by conventional techniques like microdialysis, further validating this novel 
electrochemical detection system. 
 
KYNA as an astrocyte-derived neuromodulator 
KYNA is a metabolite of the kynurenine pathway of tryptophan degradation (Kiss 
et al., 2003; see Figure 1), and is formed by the KAT-catalyzed transamination of its 
bioprecursor kynurenine in astrocytes (Guidetti et al., 2007), then is subsequently 
released into the extracellular milieu (Turski et al., 1989; see Figure 3).  Initially, KYNA 
was reported to be a broad-spectrum antagonist of excitatory amino acid (EAA) 
receptors with low (millimolar) potency (Foster et al., 1984; Swartz et al., 1990).  Later it 
was discovered that KYNA also binds competitively to the glycineB site of the NMDA-R 
(Perkins and Stone, 1982), reducing receptor activity in the absence of endogenous 
glycine levels (IC50 = ~10 µM; Kessler et al., 1989).  However, in the presence of 
physiological levels of glycine, KYNA is less likely to inhibit the NMDA-R (IC50 = ~230 
µM; Hilmas et al., 2001).  More recently, KYNA was discovered to non-competitively 
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antagonize α7 nAChRs in physiologically relevant (nanomolar) concentrations (IC50 = 
13.9 ± 8.3 µM; Hilmas et al., 2001; Lopes et al., 2007).  Thus, α7 nAChRs could be 
considered a selective target for endogenous KYNA in vivo (Stone, 2007).  Due to the 
localization of release-promoting α7 nAChR on cortical glutamatergic and cholinergic 
nerve terminals (Gotti et al., 2006; Lambe et al., 2003; Dickinson et al., 2008; Duffy et 
al., 2009) as well as the proximity of cholinergic and glutamatergic terminals in the PFC 
(Marchi et al., 2002; Rousseau et al., 2005; Wang et al., 2006; Konradsson-Geuken et 
al., 2009), the current experiments utilized the systemic administration of kynurenine to 
study the α7 nAChR-mediated relationship between KYNA and glutamate in the PFC. 
While KYNA cannot cross the blood-brain barrier easily due to its polar chemical 
structure, kynurenine promptly enters the brain following peripheral administration (Gal 
and Sherman, 1978) utilizing an amino acid carrier that transports abundant, neutral 
amino acids such as tryptophan (a precursor to kynurenine; Fukui et al., 1991).  Recent 
studies demonstrated that systemic administration of kynurenine dose-dependently 
raised KYNA levels in the PFC.  Importantly, this increase in KYNA and the subsequent 
decrease in prefrontal glutamate levels (observed in the current experiments) was 
similar to the effect induced by the local perfusion kynurenine into the PFC (Wu et al., 
2010).  These parallel data demonstrate that increasing the concentration of KYNA 
elsewhere in the brain does not seem to interfere with the KYNA-mediated regulation of 
glutamate release in the PFC.   
 
Regulation of prefrontal glutamate by KYNA: the role of α7 nAChRs   
While it is clear that nicotine binding enhances glutamatergic transmission in 
cortex, both muscarinic and nicotinic ACh receptors (and various subtypes thereof) have 
been implicated in the nicotine-induced glutamate release observed in the PFC (Toth et 
al., 1993; Vidal and Changeux, 1993).  The selective activation of α7 nAChRs by 
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choline, in particular, has been shown to elevate prefrontal glutamate levels 
(Konradsson-Geuken et al., 2009).  Likewise, the selective inhibition of α7 nAChRs by 
the non-competitive antagonist KYNA via systemic administration of kynurenine (25 and 
50 mg/kg, i.p.) results in reduced glutamate levels in the PFC (See Figures 6 and 7).  
Lastly, systemic co-administration of the positive α7 nAChR modulator galantamine (3 
mg/kg, i.p.; both 5 min pre- and 3 hrs post-injection of kynurenine), which binds to an 
allosteric site similar to that bound by KYNA (Lopes et al., 2007), attenuates this 
kynurenine-mediated reduction in extracellular glutamate (See Figure 8).  These 
observations suggest that endogenous KYNA continuously regulates extracellular 
glutamate levels in the PFC by acting at α7 nAChRs. 
 
Functional and Clinical Implications  
Dysregulations in glutamatergic and cholinergic transmission contribute to the 
pathophysiology underlying the cognitive deficits observed in schizophrenia (see 
Introduction).  As such, these experiments, which further illuminate the bi-directional 
modulation of prefrontal glutamate release by KYNA, are of critical import in 
understanding the etiology and improving treatment strategies for patients’ cognitive 
symptoms.  As schizophrenic patients have abnormally elevated KYNA levels in the PFC 
(Schwarcz et al., 2001), it is consistent that they also exhibit deficits in several cognitive 
functions that are mediated by the PFC such as working memory, attention, and 
cognitive flexibility (Andraeson, 1995).  Likewise, animals with experimentally-elevated 
KYNA levels also exhibit performance deficits in behavioral tasks requiring cognitive 
processes similar to those that are impaired in schizophrenia (Erhardt et al., 2004; 
Chess et al., 2007).  Recent clinical studies with schizophrenic patients reported modest 
improvement in cognitive functioning upon treatment with partial α7 nAChR agonists 
(Biton et al., 2007), positive α7 nAChR modulators like galantamine (Thomsen et al., 
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2010), or glutamatergic agonists (Coyle, 2006).  Taken together, these data suggest that 
adjunctive treatment strategies that are designed to attenuate the production of KYNA in 
the brain or counter its effects on α7 nAChRs may be efficacious in the treatment of 
cognitive deficits in schizophrenia (Wonodi and Schwarcz, 2010).   
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FIGURES AND FIGURE LEGENDS 
 
 
 
Figure 1.  The kynurenine pathway of tryptophan degradation (Nilsson, 2005;  
Erhardt et al., 2007). 
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Figure 2.  The transamination of kynurenine to kynurenic acid in astrocytes.  The affinity 
of the α7 nAChR for KYNA (IC50 of α7 nAChR:13.9 ± 8.3 µM; Lopes et al., 2007) is 
similar to that of the glycineB  site of the NMDA-R in the absence of glycine (IC50 of 
NMDA-R in the absence of glycine: ~10 µM; Kessler et al., 1989).  In physiological 
conditions, however, KYNA is unlikely to inhibit the NMDA-R (IC50 of NMDA-R in the 
presence of glycine: ~230 µM; Hilmas et al., 2001), whereas KYNA will negatively 
modulate α7 nAChR at nanomolar concentrations (Hilmas et al., 2001).  (Figure provided 
by Dr. Robert Schwarcz, University of Maryland) 
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Figure 3. The glutamate-sensitive microelectrode array (MEA) and the enzyme scheme 
used in the detection of glutamate.  A: Photograph of the MEA with ceramic paddle and 
recording channels.  B: High magnification of the tip of the MEA illustrating the two pairs 
of recording sites, one pair sensitive to glutamate and the remaining pair as a sentinel 
for background (non-glutamate derived) signals. C: Recording of freely moving animals. 
B 
C A 
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Figure 4.  Enzyme detection scheme.  Glutamate Recording channels:  Glutamate is 
oxidized by glutamate oxidase (GluOx), generating α-ketoglutarate and H2O2.  Because 
the MEA is maintained at a constant potential of +0.7 V, the H2O2 reporting molecule is 
oxidized, yielding two electrons.  The resulting current is then amplified and recorded by 
a FAST-16 mkI recording system.   Sentinel channels:  Extracellular glutamate reaches 
the Pt surface but in the absence of Glu Ox no oxidation current is generated.  Any 
current detected is due to endogenous electroactive molecules other than glutamate.  
 
*Nafion® is a sulfonated tetrafluoroethylene based fluoropolymer-copolymer discovered 
in the late 1960s. Its membrane exhibits an ionic gradient permeable to cations but not 
anions or electrons.  Instead of Nafion®, however, these experiments utilized the 
exclusion barrier m-PD (see Methods).  Following enzyme coating, m-PD (5.0 mM) was 
electropolymerized onto all sites using cyclic voltammetry in order to reduce access of 
potential electroactive interferents, including AA and catecholamines, to the Pt recording 
sites (cf. Figure 5).  (Figure adapted from Konradsson-Geuken, 2009) 
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Figure 5.  Representative in vitro calibration of the glutamate-sensitive MEA immediately 
prior to implantation into the PFC.  Top two tracings: glutamate-sensitive (GluOx) 
recording channels.  Bottom two tracings: sentinel background channels.  Arrows 
indicate addition of various substances to the calibration beaker.  Current (pAmp) is 
depicted along the vertical axis, and time (sec) along the horizontal axis.  Successive 
additions of glutamate (raising concentration by 20 µM/aliquot) produce a linear increase 
in the glutamate signal.  No glutamate-related changes in current are detected on the 
two sentinel channels.  Note equivalent sensitivities to the reporter molecule H2O2 on all 
four channels.  m-PD coating blocked access of negatively charged in vivo interferents 
such as ascorbic acid (AA) or dopamine (DA) (see Methods).            
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Figure 6. Photomicrograph illustrating a representative placement of MEA within 
prefrontal cortex (PFC).  (A) frontal section depicting the position of a microelectrode in 
the ventral prelimbic region of PFC.  The termination of the Pt tip of the MEA is depicted 
by the arrow above the infra-limbic (IL) cortex.  Note the modest tissue disruption 
produced by the implanted MEA.  This is consistent with previous reports from our group 
(Rutherford et al., 2007; figure adapted from Konradsson et al., 2009).    
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Figure 7.  Representative MEA tracings from a rat receiving kynurenine (KYN; 50 
mg/kg, i.p.).  Top two tracings: MEA signal from the glutamate-sensitive site (GluOx) and 
its adjacent background sentinel.  The third trace from the top reflects the self-
referenced signal (Self Ref) of the GluOx channel against the sentinel background.  
Deflections along the vertical axis reflect changes in concentration (µM), and the 
horizontal axis depicts time (hr).  The total recording session extended for 6 hrs after 
kynurenine administration (note 3 hr break in time axis).  Kynurenine produces a steady 
decline in the glutamate signal, reaching a maximum decrease of 2.1 µM by the end of 
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the recording session (see Table 1 for group data).  A control local infusion of glutamate 
(0.25 mM) rapidly elicits the characteristic phasic glutamate signal (8.5 µM increase), 
demonstrating that the MEA remained sensitive to changes in glutamate levels at the 
nadir of the kynurenine effect.  Bottom tracing: self-referenced signal from an animal that 
received a control saline injection (0.9%, i.p.), demonstrating stability of the basal 
glutamate signal. 
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Figure 8.  Representative MEA tracings from a rat receiving an injection of kynurenine 
(25 mg/kg, i.p.).  The self-referenced glutamate signal (bottom tracing; Self Ref) reveals 
that 25 mg/kg kynurenine produces a smaller maximal decrease in glutamate (1.3 µM) 
than 50 mg/kg of kynurenine (cf. Figure 7).  Note the 3 hr break in the time axis.  
Glutamate levels return to basal values within 3 ½ hrs (see Table 1 for group data).   
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Figure 9. Representative MEA tracings from a rat receiving an injection of galantamine 
(3 mg/kg, i.p.), followed, 5 min later, by kynurenine (50 mg/kg, i.p.).  Top two tracings: 
MEA signal from the glutamate-sensitive site (GluOx) and its adjacent background 
sentinel.  The third tracing, illustrating the self-referenced (Self Ref) glutamate signal, 
reveals that galantamine attenuates the amplitude of the decline and the time course to 
values similar to those seen following 25 mg/kg kynurenine (cf. Figure 8 and Table 1).  
Bottom tracing: self-referenced record from an animal that first received kynurenine (50 
mg/kg, arrow) and then, 3 hrs later at the nadir of glutamate levels, galantamine (3 
mg/kg, arrow).  The glutamate signal gradually returns to basal values following delayed 
galantamine administration, suggesting that the kynurenine-induced attenuation of 
glutamate release is consistently mediated by α7 nAChRs. 
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GLUTAMATE LEVELS FOLLOWING SYSTEMIC INJECTIONS: 
GROUP MICROELECTRODE DATA  
 
 
 
                   MEASURE 
 
KYNURENINE  
(25 mg/kg) 
   
KYNURENINE 
(50 mg/kg) 
  GALANTAMINE  
(3 mg/kg) + 
KYNURENINE  
(50 mg/kg) 
BASAL GLUTAMATE (µM)  6.0 ± 1.3    6.2 ± 1.4    6.5 ± 1.6 
           
POST‐INJECTION GLUTAMATE  
(% CHANGE FROM BASAL) 
    ‐10.6 ± 1.1a        ‐30.8 ± 5.0    ‐10.8 ± 2.3a 
           
TIME TO EFFECT (min)  16.2 ± 4.9    5.4 ± 3.6    16.3 ± 8.9 
           
TIME TO MAX EFFECT (min)    111.2 ± 23.3a    314.0 ± 20.0    77.8 ± 20.2a 
           
DURATION OF EFFECT (min)  210.3 ± 21.6a    > 6 hr       146.6 ± 13.4a,b 
           
 
 
Table 1.  All pharmacological treatments were administered via intraperitoneal (i.p.) 
injections.  Values are means ± S.E.M. with n = 5 rats/treatment group.  a = significantly 
different from kynurenine (50 mg/kg); b = significantly different from kynurenine (25 
mg/kg). 
